Many different monoclonal antibodies are already available to treat cancer. Some are licensed to treat particular types of cancer. Some newer types are still in clinical trials. Different monoclonal antibodies cause different side effects. It can take a long time to develop this type of treatment because making monoclonal antibodies can be very complicated. OMICS Group International is one of the leading 51ºÚÁϳԹÏÍøs which is publishing 700+ peer-reviewed journals. OMICS Group through its 51ºÚÁϳԹÏÍø Initiative is committed to make genuine and reliable contributions to the scientific community. It follows an 51ºÚÁϳԹÏÍø publication model that enables the dissemination of research articles to the global community free of cost. Journal of Glycobiology is one of the top journals which publish quality articles, findings dealing with Cancer Glycobiology, Glycopeptides, drug discovery and Glycomics, Fucanomes and Galactanomes, Structural Glycobiology, Membrane glycoproteins, Protein De glycosylation and carbohydrate diet and to introduce various forms of technological developments. Journal of Glycobiology is among the top journals which publish the articles related to Monoclonal antibodies . Journal of Glycobiology provide a forum for Scientists from all over the world to exchange ideas, to propagate the advancement of science.
Last date updated on May, 2025